AIP
ADPT icon

Almanack Investment Partners’s Adaptive Biotechnologies ADPT Stock Holding History

Almanack Investment Partners’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-237
Closed -$2K – 182
2022
Q3 		$2K Buy
+237
New +$2.23K ﹤0.01% 678

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Almanack Investment Partners's ADPT Position: Q4 2022 in Review

Almanack Investment Partners sold out of Adaptive Biotechnologies (ADPT) in Q4 2022, closing a stake of 237 shares — an estimated $2K sold.

Almanack Investment Partners first reported a position in ADPT in Q3 2022 and held it in 1 quarter. The position peaked at $2K in Q3 2022. 223 funds tracked by Wall St. Rank hold ADPT as of Q4 2022.

  • Almanack Investment Partners reported no remaining Adaptive Biotechnologies position as of Q4 2022 after selling out during the quarter.
  • Almanack Investment Partners sold 237 Adaptive Biotechnologies shares in Q4 2022, an estimated $2K.
  • Almanack Investment Partners first reported a position in Adaptive Biotechnologies in Q3 2022 and held it in 1 quarter.
  • Almanack Investment Partners's Adaptive Biotechnologies position peaked at $2K in Q3 2022.
  • 223 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2022.

Based on Almanack Investment Partners's 13F filing for Q4 2022, filed 9 Feb 2023.